Pierre Queiroz De Oliveira

Product Exclusivity Strategies

• Advised public and private companies on the creation and expansion of regulatory and patent exclusivity strategies to protect therapeutic products.
• Formulated and deployed patent and regulatory strategies to maximize exclusivity for repurposed and repositioned drugs products.

Patent Prosecution and Strategic Counseling

• Advised public commercial-stage regenerative medicine company on extending patent protection for its commercialized product.
• Advised a private company focused on licensing, developing and commercializing antidotes for a variety of poisons.
• Advised a private pharmaceutical company developing breakthrough therapies for urogenital conditions.
• Advised a public drug discovery company developing small molecule therapies for neurological diseases.
• Advised a private biopharmaceutical company with multiple, ongoing late-stage clinical development programs in neurosciences and dementia, rare diseases, dermatology and endocrinology.
• Advised a private drug discovery company focused on the development of small molecule drugs capable of modulating protein stability.
• Advised a biopharmaceutical company focused on the development of peptide-based therapeutics for the treatment of ocular disorders.
• Advised a specialty pharmaceutical company focused on the development of therapeutics for neonatal and pediatric patients.
• Advised multinational pharmaceutical company on patent preparation and prosecution of patents for pre-clinical oncology products.
  
   

IP Due Diligence and Transactions

• Conducted IP due diligence in support of licensing efforts for public and private biotechnology companies.
• Served as IP counsel for clinical-stage biopharmaceutical company in its US$45.2 million initial public offering.
• Served as IP counsel for a commercial-stage regenerative medicine company in its US$50 million initial public offering.
• Advised private biopharmaceutical company, conducting IP due diligence in support of strategic alliances, collaborations and partnerships with academic institutions and pharmaceutical companies to augment its late-stage clinical development programs in neurosciences and dementia.
• Advised a private early-stage drug discovery and development company in negotiating collaboration and license agreement with a global pharmaceutical company involving US$6 million in upfront payments and US$64 million in potential milestone payments.
• Conducted internal IP due diligence reviews and audits on behalf of pharmaceutical, biopharmaceutical and medical device companies in preparation for partnering, financing and public offerings.
• Provided counsel on and prepared nondisclosure agreements, consulting agreements, license agreements and collaboration/joint venture agreements for biotechnology companies.

• Co-author, "Aligning A Product's Marketing, Regulatory And IP Plans", Expert Analysis, Law360, September 8, 2017.
• Co-author, Queiroz de Oliveira PE., Miller RA. Supreme Court affords greater leeway to biosimilars in the 'patent dance'; Pepper Hamilton LLP Client Alert, June 2017.
• Speaker, "The BPCIA patent dance - what biosimilar companies need to know" CLE presentation through the Knowledge Group given on January 10, 2017
• Naran et al. Bile salts differentially sensitize esophageal squamous cells to CD95 (Fas/Apo-1 receptor) mediated apoptosis. Journal of Surgical Research, December 2011.
• Watson et al. Cytoplasmic overexpression of CD95L in esophageal adenocarcinoma cells overcomes resistance to CD95-mediated apoptosis. Neoplasia, March 2011.
• De Oliveira et al. Hypoxia-mediated regulation of Cdc25A phosphatase by p21 and miR-21.  Cell Cycle, October 2009.
• Molina et al. Zebrafish chemical screening reveals an inhibitor of Dusp6 that expands cardiac cell lineages. Nature Chemical Biology, September 2009.
• De Oliveira et al. Is a step backwards in S-phase-targeted chemotherapy a step forward? Molecular Interventions, June 2008.
• Siegfried et al. Signaling pathways involved in cyclooxygenase-2 induction by hepatocyte growth factor in non small-cell lung cancer. Molecular Pharmacology, September 2007.
• Watson et al. Inhibition of c-Met as a therapeutic strategy for esophageal adenocarcinoma. Neoplasia, November 2006.
• Lazo et al. Novel benzofuran inhibitors of human mitogen-activated protein kinase phosphatase-1.  Bioorganic Medicinal Chemistry, August 2006.
• Watson et al. Ad-IRF-1 induces apoptosis in esophageal adenocarcinoma. Neoplasia, January 2006.
• Mahidhara et al. Altered trafficking of Fas and subsequent resistance to Fas-mediated apoptosis occurs by a wild-type p53 independent mechanism in esophageal adenocarcinoma. Journal of Surgical Research, February 2005.
• El-Hefnawy et al. The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. Neoplasia, January 2005.